STRESSGEN CHANGES NAME TO NVENTA BIOPHARMACEUTICALS CORPORATION

“From Insight to Impact”

FOR IMMEDIATE RELEASE
June 1, 2006

San Diego, California USA - Stressgen Biotechnologies Corporation (TSX:SSB) announced today that it has changed its name to Nventa Biopharmaceuticals Corporation (TSX: NVN).  Nventa common shares are expected to begin trading under a new Toronto Stock Exchange symbol ‘NVN’ on June 7, 2006.  The Company’s new website is located at www.nventacorp.com.

“This is certainly an exciting time for us,” commented Gregory M. McKee, President and Chief Executive Officer at Nventa.  “In fact, so much has changed over the past year that we decided to re-brand the Company, creating a new corporate identity that coincides with our recently announced new corporate vision and clinical strategy.

“At this time,” Mr. McKee continued, “we believe Nventa is well positioned as one of the few companies focused on the development of therapeutic treatments for patients with diseases caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world and one with a clear unmet medical need and unrealized market.  We also believe that our new tagline, ‘From Insight to Impact,’ communicates our mission well:  the application of scientific insight to discover novel biopharmaceuticals that have a direct impact on patients suffering from difficult-to-treat diseases for which few, if any, treatments exist.”

Mr. McKee concluded:  “With a new management team now in place, a more open and dynamic corporate culture, a new strategic development plan to resume clinical development of our lead compound HspE7, what better time to reflect on all of our recent accomplishments and refresh our corporate image?  We look forward to continuing to report our future progress as Nventa.”

About Nventa Biopharmaceuticals Corporation

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV).  The corporation is publicly traded on the Toronto Stock Exchange.

For more information about Nventa, please visit the Company’s website located at www.nventacorp.com.

About HspE7, Lead Product Candidate:

HspE7 is a novel CoVal™ fusion therapeutic vaccine for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world.  An estimated 80 percent of sexually active men and women are infected by genital HPV at some point in their lives.  Approximately 5.5 million new sexually transmitted HPV infections are reported in the U.S. each year.  At least 20 million people in the U.S. are already infected.  HPV infection can result in diseases including internal and external genital warts and precancerous conditions, such as cervical and anal dysplasia.  Precancerous HPV-related conditions can progress into life-threatening diseases, including cervical, anal, and head and neck cancers.

Contacts:

Download a PDF file of this release